Navigation Links
Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
Date:4/23/2012

MOUNTAIN VIEW, Calif., April 23, 2012 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will report results for its fiscal quarter ended March 31, 2012, on Thursday, May 10, 2012, following the close of the U.S. financial markets. The Company will host an investor conference call and live webcast to discuss the financial results and provide a company update at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same date. The conference call, live webcast and archived replay are open to all interested parties.

To access the conference call via the Internet, go to www.alexza.com, under the "Investor Relations" link. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=PWFD3FFHN.

To access the live conference call via phone, dial 1-888-680-0894. International callers may access the live call by dialing +1-617-213-4860. The reference number to enter the call is 28704318.

The replay of the conference call may be accessed via the Internet, at www.alexza.com, or via phone at 1-888-286-8010 for domestic callers or +1-617-801-6888 for international callers. The reference number for the replay of the call is 49445384. A replay of the call will be available for two weeks following the event.

About Alexza Pharmaceuticals, Inc.
Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

ADASUVE™ (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder. Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009. In October 2010, the Company received a CRL from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010, a REMS guidance meeting with the FDA in April 2011, and the ADASUVE NDA was resubmitted in August 2011. In December 2011, the ADASUVE NDA was the subject of an advisory committee meeting. In January 2012, Alexza received notice of a 90-day extension of the PDUFA goal date, from February 4, 2012 to May 4, 2012.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer Internacional, S.A. Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries. Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011. 

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated news release and conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the potential of the Company's ADASUVE NDA resubmission to adequately address the issues in the Complete Response Letter, the timing of the FDA's review of the NDA, the eventual prospects that ADASUVE will be approved for marketing in the U.S., the timing and prospects for regulatory approval to market ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries and the adequacy of the Company's capital to support the Company's operations, the Company's ability to raise additional funds and the potential terms of such potential financings. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2011 and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza and Grupo Ferrer Amend Adasuve™ Partnership
2. Alexza Announces Proposed Public Offering of Common Stock and Warrants
3. FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval of Alexzas ADASUVE™
4. Alexza Presents Staccato® Loxapine Responder Analyses in Agitated Adult Patients with Schizophrenia or Bipolar Disease at the 2011 USPMHC Annual Conference
5. Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
6. Alexza Pharmaceuticals to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
7. Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
8. Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011
9. Alexza Pharmaceuticals to Present at the 18th Annual NewsMakers in the Biotech Industry Conference
10. Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America
11. Alexza Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)...  Compass Diversified Holdings (NYSE: CODI ) ... leading middle market businesses, announced today its consolidated operating ... First Quarter 2016 Highlights , Generated ... "Cash Flow") of $13.6 million for the first quarter ... million for the first quarter of 2016; , ...
(Date:5/4/2016)... , May 4, 2016 According ... Research entitled "Brain Computer Interface Market - Global Industry Analysis, ... global brain computer interface (BCI) market  is expected to ... market is estimated to expand at a CAGR of ... 2024. A BCI device provides collaboration between ...
(Date:5/4/2016)... 2016  It,s time for an upgrade. There are many medical recorders on the ... LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is a ... class manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... The RIDER Institute ... development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against all 18 ... 3, 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, we are ...
(Date:5/4/2016)... ... ... Nike Rugby Camp's success is due in large part to Ethan Willis ... Camps and current Nike Camp director, has offered an all abilities rugby camp staffed ... for our eighth summer here in San Diego,” says Willis. "We take great pride ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... master charity program created to assist the people of their local community. The ... nonprofit organizations and community leaders. Their hope is to bring awareness to important ...
(Date:5/4/2016)... ... May 04, 2016 , ... Dr. Elyson and Dr. Assili, dentist ... their office. Wisdom tooth removal, a common dental procedure, is performed for many adolescents ... improperly erupted, resulting in risks of complications. By providing wisdom tooth removal surgery at ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Francesca Loparco, Co-Founder ... her life forever with a same-day LASIK procedure at Christenbury Eye Center. ... Dr. Jonathan Christenbury performed her surgery the same day as her in-office consultation and ...
Breaking Medicine News(10 mins):